September 16, 2025

Lebrikizumab 24-Week Trial in Skin of Color Atopic Dermatitis

Lebrikizumab shows sustained efficacy across Fitzpatrick IV–VI at 24 weeks in atopic dermatitis.

Conexiant

September 12, 2025

Is Alopecia Areata a Marker of Elevated Cardiovascular Risk?

While alopecia has several verified comorbidities, the potential correlation with cardiovascular disease warrants further investigation.

Conexiant

September 12, 2025

Cemiplimab Reduces Recurrence in High-Risk cSCC

First adjuvant immunotherapy trial shows 23% absolute reduction in recurrence for resected cutaneous squamous cell carcinoma.

Conexiant

September 12, 2025

Maternal Health and Vitiligo: First Scoping Review Protocol

Protocol outlines review of vitiligo pregnancy outcomes, methods, and planned data mapping.

Conexiant

September 08, 2025

HS Severity Scores Declined With GLP-1 Use

Glucagon-like peptide-1 receptor agonists are linked to consistent hidradenitis suppurativa improvements across symptom, quality-of-life, and weight outcomes.

Conexiant

September 03, 2025

Vitiligo Depression Risk Varies by Race

Analysis of national health records shows vitiligo is linked to higher depression odds in certain racial and ethnic groups, highlighting variation in mental health burden across populations.

Conexiant

September 03, 2025

Study Maps Delta-Like Protein 3 and SEZ6 Across Tumor Types

Researchers highlight distinct Delta-like protein 3 and seizure-related 6 homolog patterns in neuroendocrine tumors.

Conexiant

September 02, 2025

Misconceptions Regarding Skin Cancer Risk in the United States

Investigators may have uncovered associations between the reported number of sunburns and sociodemographic characteristics as well as the prevalence of protective skin behaviors adopted by U.S. adults...

The ASCO Post

September 02, 2025

Can ctDNA Monitoring Help to Predict Melanoma Recurrence?

A new report shows how droplet digital polymerase chain reaction assays focusing on monitoring the most common mutations in the genetic code in melanoma cells—BRAF V600E and BRAF V600K—may help to pre...

The ASCO Post